Report calls for action to increase vet med pipeline
Regulatory measures across the EU have constrained the availability of an adequate range of veterinary medicines at the same time as the freer movement of animals and food products derived from them within the single market has raised the challenge of animal disease, notes an influential report. While the need for consumer protection and food safety is paramount, the rising regulatory burden of ensuring that animal medicines match the quality, efficacy and safety of human products, while ensuring that residues in food products are acceptably safe levels is difficult to achieve in a commercial environment. The cost of this process means that many products with limited sales potential are either not marketed, or are limited to the major economic species. This is especially true of the agricultural sector, accounting for around half of the market, where returns have been under pressure for some years. This is driving commercial R&D to the bloodstock and companion animal parts of the market where the potential rewards are much greater.